Progression of cardiac amyloid deposition in hereditary transthyretin amyloidosis patients after liver transplantation

References

• Benson M D. Amyloidosis. The metabolic and molecular bases of inherited disease, 8th ed, Vol. IV, Chapter 209, C R Scriver, A L Beaudet, W S Sly, D Valle, B Childs, K W Kinzler, B Vogelstein. McGraw-Hill, New York 2000; 5345–5378
   Google Scholar
• Connors L H, Lim A, Prokaeva T, Roskens V A, Costello C E. Tabulation of human transthyretin (TTR) variants, 2003. Amyloid J Protein Folding Disord 2003; 10: 160–184
   PubMed Web of Science ®Google Scholar
• Dubrey S W, Davidoff R, Skinner M, Bergethon P, Lewis D, Falk R H. Progression of ventricular wall thickening after liver transplantation for familial amyloidosis. Transplantation 1997; 64: 74–80
   PubMed Web of Science ®Google Scholar
• Stangou A J, Hawkins P N, Heaton N D, Rela M, Monaghan M, Nihoyannopoulos P, O'Grady J, Pepys M B, Williams R. Progressive cardiac amyloidosis following liver transplantation for familial amyloid polyneuropthy: implications for amyloid fibrillogenesis. Transplantation 1998; 66: 229–233
   PubMed Web of Science ®Google Scholar
• Olofsson B-O, Backman C, Karp K, Suhr O B. Progression of cardiomyopathy after liver transplantation in patients with familial amyloidotic polyneuropathy, Portuguese type. Transplantation 2002; 73: 745–751
   PubMed Web of Science ®Google Scholar
• Holmgren G, Ericzon B-G, Groth C-G, Steen L, Suhr O, Andersen O, Wallin B G, Seymour A, Richardson S, Hawkins P N, Pepys M B. Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis. Lancet 1993; 341: 1113–1116
   PubMed Web of Science ®Google Scholar
• Holmgren G, Steen L, Ekstedt J, Groth C-G, Ericzon B-G, Eriksson S, Andersen O, Karlberg I, Norden G, Nakazato M, Hawkins P N, Richardson S, Pepys M B. Biochemical effect of liver transplantation in two Swedish patients with familial amyloidotic polyneuropathy (FAP-met30). Clin Genet 1991; 40: 242–246
   PubMed Web of Science ®Google Scholar
• Herlenius G, Wilczek H E, Larsson M, Ericzon B G. Familial Amyloidotic Polyneuropathy World Transplant Registry. Ten years of international experience with liver transplantation for familial amyloidotic polyneuropathy: results from the Familial Amyloidotic Polyneurpoathy World Transplant Registry. Transplantation 2004; 77: 64–71
   PubMed Web of Science ®Google Scholar
• Westermark P, Sletten K, Johansson B, Cornwell G G, III. Fibril in senile systemic amyloidosis is derived from normal transthyretin. Proc Natl Acad Sci USA 1990; 87: 2843–2845
   PubMed Web of Science ®Google Scholar
• Pras M, Schubert M, Zucker-Franklin D, Rimon A, Franklin E C. The characterization of soluble amyloid prepared in water. J Clin Invest 1968; 47: 924–933
   PubMed Web of Science ®Google Scholar
• Liepnieks J J, Wilson D L, Benson M D. Biochemical characterization of vitreous and cardiac amyloid in Ile84Ser transthyretin amyloidosis. Amyloid 2006; 13: 170–177
   PubMed Web of Science ®Google Scholar
• Schagger H, Von Jagow G. Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation of proteins in the range from 1–100 kDA. Anal Biochem 1987; 166: 368–379
   PubMed Web of Science ®Google Scholar
• Pröpsting M J, Blaschke M, Haas R E, Genschel J, Hedrich H J, Manns M P, Schmidt H H-J. Inosine15.1 hammerhead ribozymes for targeting the transthyretin-30 mutation. Biochem Biophys Res Commun 1999; 260: 313–317
   PubMed Web of Science ®Google Scholar
• Tanaka K, Yamada T, Ohyagi Y, Asahara H, Horiuchi I, Kira J-I. Suppression of transthyretin expression by ribozymes: a possible therapy for familial amyloidotic polyneuropathy. J Neurol Sci 2001; 183: 79–84
   PubMed Web of Science ®Google Scholar
• Nakamura M, Ando Y, Nagahara S, Sano A, Ochiya T, Maeda S, Kawaji T, Ogawa M, Hirata A, Terazaki H, Haraoka K, Tanihara H, Ueda M, Uchino M, Yamamura K. Targeted conversion of the transthyretin gene in vitro and in vivo. Gene Therapy 2004; 11: 838–846
   PubMed Web of Science ®Google Scholar
• Benson M D, Kluve-Beckerman B, Zeldenrust S R, Siesky A M, Bodenmiller D M, Showalter A D, Sloop K W. Targeted suppression of an amyloidogenic transthyretin with antisense oligonucleotides. Muscle Nerve 2006; 33: 609–618
   PubMed Web of Science ®Google Scholar
• Hammarström P, Wiseman R L, Powers E T, Kelly J W. Prevention of transthyretin amyloid disease by changing protein misfolding energetics. Science 2003; 299: 713–716
   PubMed Web of Science ®Google Scholar
• Adams D, Samuel D, Goulon-Goeau C, Nakazato M, Costa P MP, Feray C, Planté V, Ducot B, Ichai P, Lacroix C, Metral S, Bismuth H, Said G. The course and prognostic factors of familial amyloid polyneuropathy after liver transplantation. Brain 2000; 123: 1495–1504
   PubMed Web of Science ®Google Scholar
• Dwulet F E, Benson M D. Primary structure of an amyloid prealbumin and its plasma precursor in a heredofamilial polyneuropathy of Swedish origin. Proc Natl Acad Sci USA 1984; 81: 694–698
   PubMed Web of Science ®Google Scholar
• Dwulet F E, Benson M D. Characterization of a transthyretin (prealbumin) variant associated with familial amyloidotic polyneuropathy type II (Indiana/Swiss). J Clin Invest 1986; 78: 880–886
   PubMed Web of Science ®Google Scholar
• Wallace M R, Dwulet F E, Conneally P M, Benson M D. Biochemical and molecular genetic characterization of a new variant prealbumin associated with hereditary amyloidosis. J Clin Invest 1986; 78: 6–12
   PubMed Web of Science ®Google Scholar
• Yazaki M, Liepnieks J J, Kincaid J C, Benson M D. Contribution of wild-type transthyretin to hereditary peripheral nerve amyloid. Muscle Nerve 2003; 28: 438–442
   PubMed Web of Science ®Google Scholar
• Benson M D, Dwulet F E. Prealbumin and retinol binding protein serum concentrations in the Indiana type hereditary amyloidosis. Arthritis Rheum 1983; 26: 1493–1498
   PubMed Web of Science ®Google Scholar
• Skinner M, Connors L H, Rubinow A, Libbey C, Sipe J D, Cohen A S. Lowered prealbumin levels in patients with familial amyloid polyneuropathy (FAP) and their non-affected but at risk relatives. Am J Med Sci 1985; 289: 17–21
   PubMed Web of Science ®Google Scholar
• Westermark P, Pitkanen P, Benson L, Vahlquist A, Olofsson B O, Cornwell G G, III. Serum prealbumin and retinol-binding protein in the prealbumin-related senile and familial forms of systemic amyloidosis. Lab Invest 1985; 52: 314–318
   PubMed Web of Science ®Google Scholar
• Benson M D, Kluve-Beckerman B, Liepnieks J J, Murrell J R, Hanes D, Uemichi T. Metabolism of amyloid proteins. The Nature and Origin of Amyloid Fibrils, Ciba Foundation Symposium 199, G R Bock, J A Goode. John Wiley & Sons Ltd; Chichester, UK. 1996; 104–118
   Google Scholar
• Longo Alves I, Hays M T, Saraiva M J. Comparative stability and clearance of Met30 transthyretin and Met119 transthyretin. Eur J Biochem 1997; 249: 662–668
   PubMedGoogle Scholar
• Bergström J, Gustavsson Å, Hellman U, Sletten K, Murphy C L, Weiss D T, Solomon A, Olofsson B-O, Westermark P. Amyloid deposits in transthyretin-derived amyloidosis: cleaved transthyretin is associated with distinct amyloid morphology. J Pathol 2005; 206: 224–232
   PubMed Web of Science ®Google Scholar
• Gorevic P D, Prelli F C, Wright J, Pras M, Frangione B. Systemic senile amyloidosis. Identification of a new prealbumin (transthyretin) variant in cardiac tissue: immunologic and biochemical similarity to one form of familial amyloidotic polyneuropathy. J Clin Invest 1989; 83: 836–843
   PubMed Web of Science ®Google Scholar
• Hermansen L F, Bergman T, Jörnvall H, Husby G, Ranløv I, Sletten K. Purification and characterization of amyloid-related transthyretin associated and familial amyloidotic cardiomyopathy. Eur J Biochm 1995; 227: 772–779
   PubMedGoogle Scholar
• Yazaki M, Mitsuhashi S, Tokuda T, Kametani F, Takei Y-I, Koyama J, Kawamorita A, Kanno H, Ikeda S-I. Progressive wild-type transthyretin deposition after liver transplantation preferentially occurs onto myocardium in FAP patients. Am J Transplant 2007; 7: 235–242
   PubMed Web of Science ®Google Scholar